Foghorn Therapeutics (FHTX) Common Equity (2019 - 2026)

Foghorn Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• On a quarterly basis, Common Equity fell 23.93% year-over-year to -$76.4 million in Q1 2026; TTM through Mar 2026 was -$76.4 million, a 23.93% decrease from a year earlier, with the FY2025 full-year figure at -$108.5 million, down 138.31% from the prior year.
• Common Equity grew to -$76.4 million in Q1 2026 per FHTX's latest filing, from -$108.5 million in the prior quarter.
• Across five years, Common Equity topped out at $72.4 million in Q1 2022 and bottomed at -$108.5 million in Q4 2025.
• The 5-year median for Common Equity is -$49.3 million (2023), against an average of -$39.0 million.
• Across the five-year window, Common Equity sank 69019.64% in 2023 and jumped 70.98% in 2024, its largest moves.
• Year by year, Common Equity stood at $112000.0 in 2022, then sank by 69019.64% to -$77.2 million in 2023, then surged by 41.02% to -$45.5 million in 2024, then slumped by 138.31% to -$108.5 million in 2025, then advanced by 29.58% to -$76.4 million in 2026.
• Per Business Quant, the three latest FHTX Common Equity figures stand at -$76.4 million (Q1 2026), -$108.5 million (Q4 2025), and -$89.7 million (Q3 2025).